Holen Sie sich die Stockscreener-App
297.72
0.97%
-2.91
Handel nachbörslich:
297.82
0.10
+0.03%
Schlusskurs vom Vortag:
$300.63
Offen:
$300.48
24-Stunden-Volumen:
170.70K
Relative Volume:
0.68
Marktkapitalisierung:
$6.55B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-10.89
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
-2.54%
1M Leistung:
+7.52%
6M Leistung:
+28.17%
1J Leistung:
-10.70%
1-Tages-Spanne:
$292.56
$302.31
1-Wochen-Bereich:
$292.56
$311.43
52-Wochen-Spanne:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
297.72 | 8.14B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Sivik Global Healthcare LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 15.3%Here's What Happened - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap UpWhat's Next? - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Sold by DAVENPORT & Co LLC - MarketBeat
Will Bio Rad Laboratories Inc. (BUW) stock gain from lower interest ratesOil Prices & Reliable Entry Point Trade Alerts - newser.com
Can technical indicators confirm Bio Rad Laboratories Inc.’s reversalAnalyst Downgrade & Expert Curated Trade Ideas - newser.com
Will Bio Rad Laboratories Inc. see short term momentumJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Newborn Screening Market Huge Growth in Future Scope 2025-2032 | Agilent Technologies, Inc., Bio-rad laboratories, Inc. - industrytoday.co.uk
Published on: 2025-10-10 05:39:23 - newser.com
Why Bio Rad Laboratories Inc. stock is favored by pension funds2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Market reaction to Bio Rad Laboratories Inc.’s recent newsPortfolio Update Summary & Weekly High Return Stock Opportunities - newser.com
945 Shares in Bio-Rad Laboratories, Inc. $BIO Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Will Bio Rad Laboratories Inc. Class stock outperform value peers2025 Sector Review & High Yield Stock Recommendations - newser.com
Why Bio Rad Laboratories Inc. Class B stock is a strong analyst pickWeekly Volume Report & AI Powered Market Entry Ideas - newser.com
Published on: 2025-10-09 05:47:16 - newser.com
Is Bio Rad Laboratories Inc. (BUWA) stock nearing a technical breakoutPortfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
Bio-Rad Extends Partnership with Gencurix Through Strategic Agreement for Droplet Digital PCR IVD Oncology Kits in Europe - the-scientist.com
Future of Polymerase Chain Reaction (PCR) Market Growth - openPR.com
Liquid Handling Systems Market Size, Scope 2032 by Key - openPR.com
Exploring the Potential of Chromatography Resins in Therapeutic Treatment Delivery - BioProcess International
Real-Time PCR And Digital PCR Market Size, Trends Analysis 2032 - openPR.com
United States Next Generation Sequencing Market Size, Trends & - openPR.com
A Look at Bio-Rad Laboratories’s Valuation Following Precision Medicine Push and New ddPCR Platform Launches - Sahm
Life Sciences Tools Market Size, Dynamics 2031 by Major - openPR.com
How Bio Rad Laboratories Inc. Class stock trades pre earningsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
What institutional flow reveals about Bio Rad Laboratories Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com
Why Bio Rad Laboratories Inc. (BUW) stock stays resilientMarket Weekly Review & High Conviction Buy Zone Picks - newser.com
What market sentiment indicators show for Bio Rad Laboratories Inc. (BUWA) stock2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Is Bio Rad Laboratories Inc. Class stock a top dividend aristocrat candidateBond Market & Safe Capital Growth Tips - newser.com
Why Bio Rad Laboratories Inc. Class B stock appears on watchlistsJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Can Bio Rad Laboratories Inc. (BUW) stock resist broad market declinesBond Market & Long-Term Safe Investment Plans - newser.com
Is Bio Rad Laboratories Inc. (BUWA) stock protected from inflationTrend Reversal & Verified Technical Signals - newser.com
Can Bio-Rad (BIO) Sustain Innovation Momentum After Leadership Loss and Diagnostics Expansion? - Sahm
(PDF) New insights into the sensitivity of Immulab reagent red blood cells compared to Bio-Rad, Grifols and QuidelOrtho - researchgate.net
Public Employees Retirement System of Ohio Increases Stake in Bio-Rad Laboratories, Inc. $BIO - Defense World
Liquid Chromatography Instruments Market Size & Strategic - openPR.com
Vector Purification Market Research, Industry Trends & Global Forecasts, 2035, Profiles of Agilent, BIA Separations, Bio-Rad, BioVision, Cytiva, Merck, Sartorius, Takara Bio, Thermo Fisher ScientificResearchAndMarkets.com - Business Wire
United States Multiplexed Diagnostics Market Share, Trends, - openPR.com
Nikhil Adhesives Limited Stock Analysis Technical Signals for YEARIPO Market Watch & Smart Beta Strategies That Actually Work - earlytimes.in
Chart based analysis of Bio Rad Laboratories Inc. trendsGap Up & Weekly High Conviction Ideas - newser.com
Bio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD oncology kits in Europe - News-Medical
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Rad Laboratories Inc-Aktie (BIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Sep 06 '25 |
Option Exercise |
0.00 |
1,535 |
0 |
2,394 |
| COREY COLLEEN | EVP, Global Human Resources |
Sep 06 '25 |
Option Exercise |
0.00 |
576 |
0 |
19,759 |
| BARRY JAMES | EVP, President, LSG |
Sep 06 '25 |
Option Exercise |
0.00 |
1,056 |
0 |
1,588 |
| Allison Schwartz | Director |
Sep 06 '25 |
Option Exercise |
0.00 |
92 |
0 |
1,489 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG |
Sep 06 '25 |
Option Exercise |
0.00 |
1,152 |
0 |
1,309 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Sep 06 '25 |
Option Exercise |
0.00 |
768 |
0 |
904 |
| SCHWARTZ NORMAN D | Chairman & CEO |
Sep 06 '25 |
Option Exercise |
0.00 |
3,455 |
0 |
444,962 |
| Allison Schwartz | Director |
Sep 01 '25 |
Option Exercise |
0.00 |
147 |
0 |
1,452 |
| BARRY JAMES | EVP, President, LSG |
Sep 01 '25 |
Option Exercise |
0.00 |
602 |
0 |
749 |
| COREY COLLEEN | EVP, Global Human Resources |
Sep 01 '25 |
Option Exercise |
0.00 |
1,102 |
0 |
19,581 |
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):